Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:GHRSOTCMKTS:NWPHFNASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.53-1.4%$3.30$2.71▼$4.73$676.09M1.23966,675 shs507,721 shsGHRSGH Research$12.76-0.5%$10.73$6.00▼$20.50$663.88M0.97187,917 shs146,854 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$37.49M0.53600 shsN/AORICORIC Pharmaceuticals$9.63-0.4%$6.15$3.90▼$14.67$820.71M1.49774,142 shs714,124 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma-1.40%+1.44%+11.71%+6.97%+8.62%GHRSGH Research-0.55%+2.08%+27.86%+16.00%+3.40%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%-1.99%ORICORIC Pharmaceuticals-0.41%+3.33%+98.15%+23.62%+21.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.2204 of 5 stars3.50.00.00.03.22.50.6GHRSGH Research1.7719 of 5 stars3.50.00.00.02.92.50.0NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AORICORIC Pharmaceuticals3.8555 of 5 stars3.50.00.04.32.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5055.81% UpsideGHRSGH Research 3.00Buy$32.00150.78% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/AORICORIC Pharmaceuticals 3.00Buy$19.1799.03% UpsideCurrent Analyst Ratings BreakdownLatest NWPHF, ABUS, ORIC, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/29/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.40M105.59N/AN/A$0.63 per share5.60GHRSGH ResearchN/AN/AN/AN/AN/AN/ANWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)GHRSGH Research-$35.59M-$0.79N/AN/AN/AN/A-20.29%-19.49%9/2/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/AORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)Latest NWPHF, ABUS, ORIC, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02GHRSGH ResearchN/A15.8315.83NWPHFNewron PharmaceuticalsN/AN/AN/AORICORIC PharmaceuticalsN/A10.5613.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%GHRSGH Research56.90%NWPHFNewron PharmaceuticalsN/AORICORIC Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%GHRSGH Research41.60%NWPHFNewron PharmaceuticalsN/AORICORIC Pharmaceuticals6.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million181.91 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableORICORIC Pharmaceuticals8085.22 million67.09 millionOptionableNWPHF, ABUS, ORIC, and GHRS HeadlinesRecent News About These CompaniesORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider SellingJune 14 at 2:12 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Average PT from AnalystsJune 14 at 1:29 AM | americanbankingnews.comWhat Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?June 13 at 1:01 PM | zacks.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down on Insider SellingJune 12 at 10:27 AM | marketbeat.comMillennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 12 at 3:08 AM | marketbeat.comBrokers Issue Forecasts for ORIC FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 SharesJune 11 at 8:50 PM | marketbeat.comOric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholdersJune 11 at 7:33 PM | msn.comCantor Fitzgerald Weighs in on ORIC FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from AnalystsJune 11 at 2:06 AM | marketbeat.comInsider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells 2,600 Shares of StockJune 10, 2025 | insidertrades.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $26,026.00 in StockJune 9, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DEJune 8, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?June 6, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 6, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 7.6% Higher - Still a Buy?June 4, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.5% - Should You Sell?June 3, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Time to Buy?June 3, 2025 | marketbeat.comWall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should KnowJune 2, 2025 | zacks.comResearch Analysts Set Expectations for ORIC FY2025 EarningsJune 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockAdvance Auto Parts Jumps on Surprise Earnings BeatBy Chris Markoch | May 23, 2025View Advance Auto Parts Jumps on Surprise Earnings BeatNWPHF, ABUS, ORIC, and GHRS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.53 -0.05 (-1.40%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.60 +0.08 (+2.12%) As of 06/13/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.GH Research NASDAQ:GHRS$12.76 -0.07 (-0.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$12.74 -0.02 (-0.16%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 06/12/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.ORIC Pharmaceuticals NASDAQ:ORIC$9.63 -0.04 (-0.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.62 -0.01 (-0.05%) As of 06/13/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
